NCT04448301 2025-11-06
PC001- A Study to Evaluate the Usability of PointCheck
Leuko Labs, Inc.
Phase NA Completed
Clinical Trials
97 trialsNCT04526886 2025-10-06
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT01916057 2025-09-08
CANHPARI
Assistance Publique - Hôpitaux de Paris
Phase NA Completed
NCT04081753 2024-09-23
REMEDY
Augusta University
Phase NA Completed
NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT05283616 2024-03-19
Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Completed
NCT00020371 2024-03-04
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
NCT00004192 2023-12-27
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT05963334 2023-07-27
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
Cairo University
Phase 1/2 Completed
NCT03252431 2023-07-03
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT02231879 2023-04-07
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
National Institutes of Health Clinical Center (CC)
Phase 2/3 Completed
NCT05221593 2022-10-21
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients
Al-Azhar University
Phase 3 Completed
NCT03087227 2022-05-09
NEUTROSIS
University of Paris 13
Phase NA Completed
NCT00345345 2022-05-03
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01724866 2022-04-15
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02643420 2022-03-02
ADVANCE
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02953340 2022-03-02
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
NCT04466137 2022-02-09
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 3 Completed
NCT02190721 2021-12-10
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT03019939 2021-10-26
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02872103 2021-05-05
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT01371656 2020-12-07
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group
Phase 3 Completed
NCT04009941 2020-10-28
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
Peking University
Phase 4 Completed
NCT00002866 2020-04-01
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 1 Completed
NCT01629082 2019-12-17
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04187755 2019-12-06
Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
Indonesia University
Phase 4 Completed
NCT02522234 2019-11-21
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1/2 Completed
NCT03251768 2019-09-13
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Tianjin SinoBiotech Ltd.
Phase 2 Completed
NCT04000711 2019-06-27
Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia
Hospital Infantil de Mexico Federico Gomez
Phase NA Completed
NCT02324231 2019-02-21
SPOG 2015 FN Definition. A Multi-center Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia
Swiss Pediatric Oncology Group
Phase NA Completed
NCT01648322 2018-10-03
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 2 Completed
NCT02282215 2018-09-27
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Cellerant Therapeutics
Phase 2 Completed
NCT01484015 2018-07-18
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
Phase 1 Completed
NCT02005458 2018-07-17
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 2 Completed
NCT01619423 2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2 Completed
NCT02521441 2018-02-23
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
EVIVE Biotechnology
Phase 2 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT01516736 2017-08-30
PROTECT2
Sandoz
Phase 3 Completed
NCT03246009 2017-08-11
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
Tianjin SinoBiotech Ltd.
Phase 1 Completed
NCT01735175 2017-08-07
PROTECT-1
Sandoz
Phase 3 Completed
NCT00335478 2017-05-09
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00686543 2017-04-07
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT01523431 2017-03-30
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2/3 Completed
NCT00044486 2017-03-10
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00364468 2017-03-03
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT02778763 2016-07-20
Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis
BioLab 612 LLC
Phase 2 Completed